Table 3.
Distribution of DQB1*03, DRB1*11, and DRB3*02 in HCV-Seropositive Persons With and Without Spontaneous Viral Clearance
| HLA Genotype | % All Patients | % White Patientsa | % Black Patients | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype Frequency | R (n = 23) |
C (n = 70) |
OR (95% CI, P-value) | R (n = 13) |
C (n = 28) |
OR (95% CI, P-value) | R (n = 10) |
C (n = 42) |
OR (95% CI, P-value) |
| DQB1*03 | 73.9 | 51.4 | 2.7 (0.9–7.6, 0.059) | 92.3 | 53.6 | 10.4 (1.2–91.2, 0.031) | 50.0 | 50.0 | 1.0 (0.3–4.0, 1.000) |
| DRB1*11 | 39.1 | 27.1 | 1.7 (0.6–4.6, 0.277) | 53.8 | 14.3 | 7.0 (1.5–32.0, 0.019) | 20.0 | 35.7 | 0.5 (0.1–2.4, 0.467) |
| DRB3*02 | 60.9 | 44.3 | 2.0 (0.7–5.1, 0.167) | 69.2 | 21.4 | 8.3 (1.9–36.4, 0.005) | 50.0 | 59.5 | 0.7 (0.2–2.7, 0.725) |
| DQB1*03-DRB3*02 | 58.5 | 24.3 | 4.1 (1.5–10.9, 0.004) | 69.2 | 14.3 | 13.5 (2.8–65.8, 0.001) | 40.0 | 31.0 | 1.5 (0.4–6.2, 0.711) |
| DRB1*11-DRB3*02 | 39.1 | 25.7 | 1.9 (0.7–5.0, 0.219) | 53.8 | 14.3 | 7.0 (1.5–32.0, 0.019) | 20.0 | 33.3 | 0.5 (0.1–2.7, 0.705) |
| DQB1*03-DRB1*11 | 39.1 | 21.4 | 2.4 (0.9–6.5, 0.092) | 53.8 | 14.3 | 7.0 (1.5–32.0, 0.019) | 20.0 | 26.2 | 0.7 (0.1–3.8, 1.000) |
| DQB1*03-DRB1*11-DRB3*02 | 39.1 | 20.0 | 2.6 (0.9–7.1, 0.065) | 53.8 | 14.3 | 7.0 (1.5–32.0, 0.019) | 20.0 | 23.8 | 0.8 (0.1–4.4, 1.000) |
Percent of individuals positive for the HLA types (either alone or in combination) is shown among all, black, and white patients with spontaneous HCV clearance (R) or chronic infection (C) with respective odds ratios. 95% confidence intervals, and P-values calculated by chi-squared and Fisher’s exact test. Because significant associations for HLA DQB1*03 and DRB1*11 were anticipated, the P-values were not further corrected. For DRB3*02, the number of comparisons was 3 (adjusted α = 0.07), resulting in corrected P-value of 0.015, which remained significant.
All HLA DRB1*11+ white patients (n = 11) also carried DQB1*03 and DRB3*02.